Filippova 1997.

Methods	8‐week lipid lowering diet washout period 12‐week before and after trial
Participants	20 patients with CAD Total cholesterol ≥ 5.2 mmol/L (201 mg/dL) one patient died 6 weeks before the start of the fluvastatin dosing no exclusion criteria reported 19 patients were included in the efficacy analysis Fluvastatin 20 mg/day baseline TC : 7.62 mmol/L (295 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 5.17 mmol/L (200 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.07 mmol/L (41 mg/dL) Fluvastatin 20 mg/day baseline triglycerides: 2.84 mmol/L (252 mg/dL)
Interventions	Fluvastatin 20 mg/day for 6 weeks Fluvastatin 40 mg/day for 6‐12 weeks
Outcomes	per cent change from baseline at 6 weeks of blood LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	Fluvastatin 40 mg/day for 6‐12 weeks group was not included in the efficacy analysis Total cholesterol data were not included in the efficacy analysis because the calculated value was different by more than 10% from the given value SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	5% participants were not included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported